MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY A joint research team from Russia and the U.K. has demonstrated the possibility of developing a new type of anti-neoplastic drugs based on nanoMIPs, or “plastic antibodies.” NanoMIPs are synthetic polymers that can function as antibodies, selectively binding to target proteins on the surface of cancer cells. This approach could lead...
Tag: <span>anti-EGFR drug</span>
Post
Tarloxitinib puts tumor-seeking tail on anti-EGFR drug to precisely target lung cancer
EGFR is a common genetic target in lung cancer, but not all EGFR mutations are created equal. Patients with a type of EGFR anomaly called an “EGFR exon 20 insertion” often fail to respond to existing drugs targeting EGFR. Previous work shows this is because it simply takes a much higher concentration of anti-EGFR drugs...